Turku PET Centre provides vartiety of research services for pharma.
Examples of recent Phase I-III clinical studies at Turku PET Centre:
Occupancy study of antidepressant target in the brain of healthy volunteers – provided important guidance for dose level selection in Phase II trials and helped to reach a no-go decision before Phase III (Bergström M et al., Biol Psychiatry 2004, 55:1007-12)
The study investigating the effects of 12-month enzyme replacement therapy on myocardial perfusion in patients with Fabry disease. (Kalliokoski RJ et al. J Inherit Metab Dis. 2006 Feb;29(1):112-8.)
Investigation of the estradiol-drospirenone hormone treatment on myocardial perfusion reserve in postmenopausal women with angina pectoris. (Knuuti J, et al. Am J Cardiol. 2007 Jun 15;99(12):1648-52.)
A 16-week randomized, double-blind, placebo-controlled study of Rosiglitazone on myocardial glucose uptake in patients with type 2 diabetes and coronary artery disease. (Lautamäki R, et al Diabetes. 2005 Sep;54(9):2787-94.)
Occupancy study of therapeutic target in the brain of Alzheimer’s patients and healthy control subjects – provided important information for Phase II dose selection (Hirvonen J et al., Clin Pharmacol Ther 2009, 85:506-12)
Amyloid imaging study to assess efficacy of anti-amyloid therapy in Alzheimer’s disease – suggested that the treatment has anti-amyloid efficacy and that [11C]-PiB PET imaging is useful in assessing the effects of potential anti-amyloid treatments in Alzheimer’s disease (Rinne JO et al., Lancet Neurol 2010, 9:363-72)